IPG-ATENOLOL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

ATENOLOL

Prieinama:

MARCAN PHARMACEUTICALS INC

ATC kodas:

C07AB03

INN (Tarptautinis Pavadinimas):

ATENOLOL

Dozė:

50MG

Vaisto forma:

TABLET

Sudėtis:

ATENOLOL 50MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

10/30/100/500

Recepto tipas:

Prescription

Gydymo sritis:

BETA-ADRENERGIC BLOCKING AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0113847002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2017-02-03

Prekės savybės

1
PRODUCT MONOGRAPH
PR
IPG-ATENOLOL
Atenolol Tablets, BP
50 mg and 100 mg
Beta-adrenergic receptor blocking
agent
MARCAN PHARMACEUTICALS INC.
DATE OF PREPARATION:
2 GURDWARA
RD, # 112
MARCH 18, 2011
OTTAWA, ONTARIO
K2E 1A2, CANADA DATE OF REVISION:
www.marcanpharma.com
SEPTEMBER 24, 2021
Control #: 249790
2
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
IPG-ATENOLOL
Atenolol Tablets, BP
50 mg and 100 mg
THERAPEUTIC CLASSIFICATION
Beta-adrenergic receptor blocking
agent
ACTION AND CLINICAL PHARMACOLOGY
Atenolol is a beta
1
-selective, beta adrenergic blocking
agent, devoid of membrane stabilizing
or
intrinsic
sympathomimetic
(partial
agonist)
activities.
It is a racemic mixture
and the
beta
1
properties reside in the S (-) enantiomer. Beta
1
-selectivity decreases with increasing dose.
The mechanism of the antihypertensive effect has not been established.
Among the factors that may
be involved are:
(a)
competitive
ability
to antagonize
catecholamine-induced
tachycardia at the beta-receptor
sites in the heart, thus decreasing cardiac output
(b)
inhibition
of renin release by the kidneys
(c)
inhibition
of the vasomotor centres
The mechanism
of the anti-anginal
effect is also uncertain. An important
factor may be the
reduction of myocardial oxygen requirements by blocking
catecholamine-induced increases in heart
rate, systolic blood pressure, and the velocity and extent of
myocardial contraction.
In man atenolol reduces both isoproterenol-and
exercise-induced increases in heart rate over the
dose range of 50 to 200 mg. At an oral dose of 100 mg the beta
1
-blocking effects persist for at least
24 hours; the reduction in exercise-induced heart rate increase being
about 32% and 13%, 2 and 24
hours after dosing,
respectively. The logarithm
of the plasma atenolol
level correlates with the
degree of beta
1
-blockade but not with the antihypertensive effect.
3
PHARMACOKINETICS
Approximately 40 to 50 % of an oral dose of atenolol is absorbed from
the gastrointestinal tract, the
remainder being excreted unchanged in the feces. Peak plasm